AnaptysBio, Inc. (NASDAQ:ANAB) Stock Has Average Target Price of $79.85 According to Brokerages

AnaptysBio, Inc. (NASDAQ:ANAB) has received an average recommendation of “Moderate Buy” from the sixteen ratings firms that are covering the company, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, three have issued a hold rating and twelve have assigned a buy rating to the company. The average 12 month price target among brokers that have updated their coverage on the stock in the last year is $79.15.

ANAB has been the subject of several research analyst reports. Wolfe Research reiterated an “outperform” rating and set a $78.00 target price on shares of AnaptysBio in a research note on Monday, August 31st. HC Wainwright restated a “buy” rating and issued a $95.00 price target on shares of AnaptysBio in a research note on Tuesday, September 22nd. Scotiabank downgraded AnaptysBio to a “hold” rating and set a $70.00 price target for the company. in a report on Tuesday, August 25th. Zacks Research cut shares of AnaptysBio from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, June 2nd. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of AnaptysBio in a report on Tuesday, September 22nd.

AnaptysBio Stock Performance

AnaptysBio stock opened at $50.37 on Wednesday. AnaptysBio has a 52 week low of $16.67 and a 52 week high of $72.36. The stock has a market capitalization of $1.51 billion, a P/E ratio of 9.38 and a beta of 0.71. The stock has a 50-day simple moving average of $55.32 and a 200 day simple moving average of $58.90.

AnaptysBio (NASDAQ:ANAB) last announced its quarterly earnings results on Monday, September 21st. The biotechnology company reported $5.11 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.46) by $5.57. The firm had revenue of $27.49 million for the quarter, compared to the consensus estimate of $14.06 million. AnaptysBio had a return on equity of 112.00% and a net margin of 82.37%.During the same quarter in the previous year, the business earned ($1.30) earnings per share. Research analysts forecast that AnaptysBio will post -1.3 earnings per share for the current year.

Institutional Trading of AnaptysBio

Hedge funds and other institutional investors have recently modified their holdings of the stock. Tema ETFs LLC grew its stake in AnaptysBio by 0.6% during the second quarter. Tema ETFs LLC now owns 31,270 shares of the biotechnology company’s stock worth $2,111,000 after buying an additional 201 shares in the last quarter. Larson Financial Group LLC raised its position in shares of AnaptysBio by 21.2% in the 4th quarter. Larson Financial Group LLC now owns 1,624 shares of the biotechnology company’s stock valued at $79,000 after buying an additional 284 shares in the last quarter. Arizona State Retirement System lifted its holdings in shares of AnaptysBio by 13.5% during the 2nd quarter. Arizona State Retirement System now owns 4,363 shares of the biotechnology company’s stock worth $295,000 after acquiring an additional 518 shares during the period. Persistent Asset Partners Ltd bought a new stake in shares of AnaptysBio during the 2nd quarter worth approximately $39,000. Finally, Caitong International Asset Management Co. Ltd boosted its position in shares of AnaptysBio by 940.8% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 1,530 shares of the biotechnology company’s stock worth $74,000 after acquiring an additional 1,383 shares in the last quarter.

AnaptysBio Company Profile

AnaptysBio, Inc is a clinical-stage biotechnology company focused on discovering and developing antibody-based medicines for cancer and immune-mediated diseases. The company’s programs are designed to modulate immune-cell signaling and address conditions in which the immune system is either insufficiently active, as in cancer, or overly active, as in autoimmune and inflammatory disorders.

AnaptysBio’s pipeline has included rosnilimab, an investigational antibody targeting CD200R1, and other immune-cell modulators aimed at autoimmune and inflammatory diseases.